NYSE:DPLO - Diplomat Pharmacy Stock Price, News & Analysis

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings data on Friday, August, 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The company's revenue was down 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. View Diplomat Pharmacy's Earnings History.

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, August, 9th. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

13 brokerages have issued twelve-month price targets for Diplomat Pharmacy's shares. Their predictions range from $5.50 to $30.00. On average, they expect Diplomat Pharmacy's stock price to reach $10.1250 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

News coverage about DPLO stock has been trending negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Diplomat Pharmacy.

Diplomat Pharmacy saw a drop in short interest in July. As of July 15th, there was short interest totalling 8,278,800 shares, a drop of 7.6% from the June 15th total of 8,959,100 shares. Based on an average daily volume of 765,200 shares, the short-interest ratio is currently 10.8 days. Currently, 14.6% of the shares of the company are sold short. View Diplomat Pharmacy's Current Options Chain.

Some companies that are related to Diplomat Pharmacy include Petmed Express (PETS), Rite Aid (RAD), 111 (YI), China Jo-Jo Drugstores (CJJD), HealthWarehouse.com (HEWA) and Dougherty's Pharmacy (MYDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), Gilead Sciences (GILD), General Electric (GE), Activision Blizzard (ATVI), CVS Health (CVS), Cannabis Sativa (CBDS), Horizon Therapeutics (HZNP), Servicesource International (SREV), Ford Motor (F) and Cara Therapeutics (CARA).

Diplomat Pharmacy's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.25%), Stephens Inc. AR (8.83%), Vanguard Group Inc. (7.64%), JPMorgan Chase & Co. (1.94%), Northern Trust Corp (1.72%) and Invesco Ltd. (1.63%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Trexquant Investment LP, Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, Morgan Stanley, Kings Point Capital Management and Comerica Bank. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Philip R Hagerman. View Insider Buying and Selling for Diplomat Pharmacy.

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Stephens Inc. AR, JPMorgan Chase & Co., BlackRock Inc., Invesco Ltd., D. E. Shaw & Co. Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc. and Renaissance Technologies LLC. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DPLO stock can currently be purchased for approximately $5.32.

Diplomat Pharmacy has a market capitalization of $403.42 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]